Brief: Sinopharm Group Reaches Strategic Cooperation With TSB Therapeutics (Beijing)
31/03/2022 16:33
March 31 (Reuters) - Sinopharm Group Co Ltd 1099.HK :
* HAS REACHED STRATEGIC COOPERATION WITH TSB THERAPEUTICS
(BEIJING), UNIT OF BRII BIOSCIENCES
* UNDER AGREEMENT, BOTH PARTIES WILL WORK TOGETHER TO
PROMOTE
COMMERCIAL PROGRESS OF COVID-19 MONOCLONAL NEUTRALIZING ANTIBODY
THERAPY
Source text for Eikon: ID:nHKS8VzTht
Further company coverage: 1099.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR